Results 121 to 130 of about 21,646 (232)

The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients

, 2013
Christopher R Ellis, Daniel W KaiserVanderbilt Heart and Vascular Institute, Nashville, TN, USAAbstract: The use of novel oral anticoagulants (NOACs) for stroke and systemic embolism prevention in the setting of specifically non valvular atrial ...
Ellis CR, Kaiser DW
core  

Dabigatran (October 2011)

Cleveland Clinic Journal of Medicine, 2012
Readers comment on the oral anticoagulant dabigatran (October 2011), and screening for cervical cancer (November 2011).
openaire   +2 more sources

Reasons of discontinuation of dabigatran.

, 2014
Reasons of discontinuation of dabigatran.
Gilberto Ka Kit Leung (607487), Chi Wai Ho (607481), Koon Ho Chan (607485), Esther W. Chan (607486), Mei Han Ho (607480), Emmanuel Cheung (607482), Jo Jo Hai (607484), Hung Fat Tse (323962), Pak Hei Chan (607483), Chung Wah Siu (607488)   +9 more
core   +1 more source

Dabigatran versus warfarin in atrial fibrillation: Multicenter experience in Turkey

, 2016
Safety issues have been raised about dabigatran. We aimed to investigate the occurrence of safety outcomes in patients who had atrial fibrillation and a risk of stroke.
Yaylali, Y. T., Senol, H., Yaylalı, Yalın Tolga, Aslan, O., Ugur-Yildiz, M., Ozdemir, M., Şenol, Hande, Aslan, Onur, Yildirim, S., Yurtdas, M.   +9 more
core   +1 more source

Dabigatran accumulation in acute kidney injury: is more better than less to prevent bleeding? A case report

International Journal of Emergency Medicine
Dabigatran is an oral anticoagulant that is mainly renally excreted. Despite its efficacy in preventing thromboembolic events, concerns arise regarding bleeding complications in patients with acute kidney injury. Idarucizumab is its specific antidote and
Rafik Matbouli, Olivier Pantet, Julien Castioni, Nima Vakilzadeh, Lorenzo Alberio, Olivier Hugli   +5 more
doaj   +1 more source

Dabigatran etexilate and reduction in serum apolipoprotein B

, 2016
Objective Carboxylesterases, which convert dabigatran etexilate to its active form, dabigatran, have also been shown to influence lipoprotein metabolism, although any pleotropic effects of the drug based on this possible mechanism has not been evaluated.
Wallentin, Lars,, Yusuf, Salim,, Wang, Jia,, Siegbahn, Agneta,, Ezekowitz, Michael,, Themeles, Ellison,, Connolly, Stuart,, Oldgren, Jonas,, Pare, Guillaume,, Reilly, Paul,, Joseph, Philip,, Eikelboom, John,   +11 more
core   +1 more source

Anticoagulant Related Nephropathy Induced by Dabigatran

, 2018
We describe a case of biopsy-proven dabigatran related nephropathy in a patient without underlying IgA nephropathy. To date, dabigatran related nephropathy was only reported in patients with concurrent or undiagnosed IgA nephropathy, suggesting that it ...
Mahra Nourbakhsh, Alan Box, Nazia Sharfuddin, Daniel A. Muruve, Hallgrimur Benediktsson   +4 more
core   +1 more source

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism

, 2013
BACKGROUND: Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism.
Schellong, S, Kvamme, AM, Mismetti, P, Eriksson, H, Friedman, J, DI MINNO, GIOVANNI, Schulman, S1, Kakkar, AK, Goldhaber, SZ, Kearon, C, Goldhaber, S, Kakkar A, Schulman, S, Baanstra, D   +13 more
core   +1 more source

Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin

, 2010
Dabigatran is a highly selective, reversible, and potent thrombin inhibitor and is orally available as the prodrug, dabigatran etexilate. It has shown antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action and predictable ...
Joanne van Ryn, Norbert Hauel, Andreas Clemens, Wolfgang Wienen, Wolfgang G. Eisert, Joachim Stangier   +5 more
core   +1 more source

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal

, 2018
Marco Proietti,1–3 Giuseppe Boriani4 1Department of Neuroscience, IRCCS – Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy; 2Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK ...
Proietti M, Boriani G
core